Researchers from Chulalongkorn University have successfully developed MUC1-targeting CAR T cells engineered to secrete an anti-PD-1 antibody, derived from nivolumab, to enhance their effectiveness against solid tumors. These modified CAR T cells, known as MUC1.PD1, maintained antigen-specific cytotoxicity and exhibited increased proliferation and reduced PD-1 expression after repeated antigen stimulation indicating resistance to T cell exhaustion.
In a cholangiocarcinoma xenograft model, MUC1.PD1 CAR T cells significantly reduced tumor growth compared to conventional CAR T cells.
This study demonstrates the therapeutic potential of combining CAR T cell therapy with localized immune checkpoint blockade, offering a promising strategy to improve treatment outcomes in solid tumors.
Funding
Original Paper
Title of original paper:
Journal: JThe 29th Annual Meeting of Japanese Association of Cancer Immunology
DOI: https://jaci2025.com/en/index.html